A Phase 2 interventional study of Tapinarof cream, 1% in Atopic Dermatitis, sponsored by Organon and Co. Completed at 10 sites in 2 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Organon and Co · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 2, and was the 9th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 168 across the 12 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 5 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
14 studies in Dermatitis, Atopic by Organon & Co.: none open now, 1 under way, 1 of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 14 studies in Dermatitis, Atopic by Organon & Co., this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 4 in phase 2, and was the 13th registered.
Organon & Co.’s Dermatitis, Atopic studies by the year they started, since 2003.
1 of the studies testing tapinarof in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, from their registry updates:
Among Organon & Co.’s 14 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
This is a 4-week open-label study in which subjects will be assigned to receive tapinarof cream, 1% once daily for 4 weeks. At the end of the 4-week study treatment, qualified subjects will have the option to enroll in an open-label, long-term extension study for an additional 48 weeks of treatment. Subjects who do not participate in the open-label, long-term extension study will complete a follow-up visit approximately one week after the end of treatment in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tapinarof (DMVT-505) cream, 1% applied topically once daily
Drug: Tapinarof cream, 1%
Tapinarof cream, 1% applied topically once daily
Also known as: DMVT-505
Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants that Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs).
Time frame: Baseline to Day 28 for subjects enrolling in Long-Term Extension (LTE), otherwise to Day 35
Change From Baseline in Laboratory Values (U/L)
Change in laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (g/L)
Change in laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (mmol/L)
Change in laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (Umol/L)
Change in laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (10^9 Cells/L)
Change in laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (%)
Change in laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (pg)
Change in Ery. mean corpuscular hemoglobin laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (fL)
Change in Ery. mean corpuscular volume laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (10^12 Cells/L)
Change in Erythrocytes laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Laboratory Values (L/L)
Change in Hematocrit laboratory values was assessed for clinical relevance
Time frame: Baseline to Day 28
Mean Change in Local Tolerability Scale (LTS)
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale. 0 indicates no irritation and 4 indicates Very Severe irritation.
Time frame: Baseline to Day 28
Tapinarof Plasma PK Parameters on Day 1: AUC0-τ
The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.
Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Tapinarof Plasma PK Parameters on Day 1: Cmax
The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.
Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Tapinarof Plasma PK Parameters on Day 1: Tmax
The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.
Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Tapinarof Plasma Concentration: Cτ
The Cτ is a pharmacokinetic parameter that is the last quantifiable concentration determined directly from individual concentration-time data
Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)
Change From Baseline in Vital Signs (Beats/Min)
Change in pulse vital signs was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Vital Signs (mmHg)
Change in Blood Pressure vital signs was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Vital Signs (C)
Change in Temperature vital signs was assessed for clinical relevance
Time frame: Baseline to Day 28
Change From Baseline in Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
Time frame: Baseline to Day 28
Number of Subjects Who Have a Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Score of Almost Clear (0 or 1) and at Least a 2-grade Reduction From Baseline
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
Time frame: Baseline to Day 28
Number of Subjects With ≥50%, Improvement in Eczema Area and Severity Index (EASI) Score
The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.
Time frame: Baseline to Day 28
Number of Subjects With ≥75%, Improvement in Eczema Area and Severity Index (EASI) Score
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Day 28
Number of Subjects With ≥90%, Improvement in Eczema Area and Severity Index (EASI) Score
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Day 28
Mean Change in Eczema Area and Severity Index EASI From Baseline to Day 28
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Day 28
Percent Change in Eczema Area and Severity Index EASI From Baseline to Day 28
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Day 28
Mean Change in Percent of Total Body Surface Area (%BSA) Affected
The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.
Time frame: Baseline to Day 28
Percent Change in Percent of Total Body Surface Area (%BSA) Affected
The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.
Time frame: Baseline to Day 28
Mean Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting (0 indicates no inflammatory signs of atopic dermatitis and 4 indicates disease is widespread). The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. %BSA is a static assessment made without reference to previous scores and will be evaluated 0-100%. The computation is referenced below, and no unit is applicable for this outcome measure. A negative change indicates improvement in disease. \[Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)\]
Time frame: Baseline to Day 28
Percent Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Score of 0 indicates no inflammatory signs of atopic dermatitis and a 4 indicates disease is widespread in extent. The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores. Computation: Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)
Time frame: Baseline to Day 28
Mean Change in Average Weekly Peak Pruritus Numerical Rating Scale (PP-NRS) Score
The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.
Time frame: Baseline to Day 28
Proportion of Subjects With a Baseline Peak Pruritus Numerical Rating Scale (PP-NRS) Score ≥4 Who Achieved ≥4-point Reduction in PP-NRS Score
The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.
Time frame: Baseline to Day 28
Participants from the DMVT-505-2104 study had the option to participate in the open label extension study (DMVT-505-3103, NCT05142774).
| Milestone | Tapinarof Cream |
|---|---|
| Started | 36 |
| Completed | 32 |
| Not completed | 4 |
Number of Participants that Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs).
| Participants | Tapinarof Cream |
|---|---|
| Experienced an AE | 8 |
| Experienced an SAE | 0 |
Change in laboratory values was assessed for clinical relevance
| U/L | Tapinarof Cream |
|---|---|
| Alanine aminotransferase (U/L) | 1.9 ± 10.80 |
| Alkaline phosphatase (U/L) | 0.7 ± 52.95 |
| Aspartate aminotransferase (U/L) | 0.6 ± 6.44 |
Change in laboratory values was assessed for clinical relevance
| g/L | Tapinarof Cream |
|---|---|
| Albumin (g/L) | -0.7 ± 2.72 |
| Protein (g/L) | -0.5 ± 4.20 |
| Ery. mean corpuscular HGB Concentration (g/L) | -1.7 ± 7.68 |
| Hemoglobin (g/L) | 0.0 ± 7.61 |
Change in laboratory values was assessed for clinical relevance
| mmol/L | Tapinarof Cream |
|---|---|
| Bicarbonate (mmol/L) | -0.3 ± 2.16 |
| Calcium (mmol/L) | -0.006 ± 0.0846 |
| Chloride (mmol/L) | 0.0 ± 2.99 |
| Glucose (mmol/L) | 0.20 ± 0.819 |
| Potassium (mmol/L) | 0.08 ± 0.532 |
| Sodium (mmol/L) | 0.1 ± 1.98 |
| Blood urea nitrogen (mmol/L) | -0.06 ± 0.989 |
Change in laboratory values was assessed for clinical relevance
| Umol/L | Tapinarof Cream |
|---|---|
| Bilirubin (umol/L) | -0.34 ± 3.700 |
| Enzymatic Creatinine (umol/L) | -0.9 ± 7.66 |
| Urate (umol/L) | -6.0 ± 52.16 |
Change in laboratory values was assessed for clinical relevance
| 10^9 cells/L | Tapinarof Cream |
|---|---|
| Basophils (10^9/L) | 0.01 ± 0.048 |
| Eosinophils (10^9/L) | 0.00 ± 0.419 |
| Leukocytes (10^9/L) | 0.71 ± 2.451 |
| Lymphocytes (10^9/L) | 0.38 ± 1.095 |
| Monocytes (10^9/L) | -0.06 ± 0.175 |
| Neutrophils (10^9/L) | 0.36 ± 2.124 |
| Platelets (10^9/L) | -34.8 ± 95.27 |
Change in laboratory values was assessed for clinical relevance
| % of cells | Tapinarof Cream |
|---|---|
| Basophils/Total cells (%) | 0.05 ± 0.343 |
| Eosinophils/Total cells (%) | -0.13 ± 4.606 |
| Lymphocytes/Total cells (%) | 0.81 ± 11.023 |
| Monocytes/Total cells (%) | -0.81 ± 2.662 |
| Neutrophils/Total cells (%) | 0.08 ± 12.693 |
| Reticulocytes/Erythrocytes (%) | 0.06 ± 0.377 |
Change in Ery. mean corpuscular hemoglobin laboratory values was assessed for clinical relevance
| pg | Tapinarof Cream |
|---|---|
| Change From Baseline in Laboratory Values (pg) | 0.26 ± 0.787 |
Change in Ery. mean corpuscular volume laboratory values was assessed for clinical relevance
| fL | Tapinarof Cream |
|---|---|
| Change From Baseline in Laboratory Values (fL) | 1.26 ± 1.973 |
Change in Erythrocytes laboratory values was assessed for clinical relevance
| 10^12 cells/L | Tapinarof Cream |
|---|---|
| Change From Baseline in Laboratory Values (10^12 Cells/L) | -0.055 ± 0.2481 |
Change in Hematocrit laboratory values was assessed for clinical relevance
| L/L | Tapinarof Cream |
|---|---|
| Change From Baseline in Laboratory Values (L/L) | 0.002 ± 0.0228 |
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale. 0 indicates no irritation and 4 indicates Very Severe irritation.
| Units on a scale | Tapinarof Cream |
|---|---|
| Baseline | 0.2 ± 0.68 |
| Day 28 | 0.1 ± 0.40 |
The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.
| pg*h/mL | Tapinarof Cream |
|---|---|
| Tapinarof Plasma PK Parameters on Day 1: AUC0-τ | 4690 ± 5600 |
The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.
| pg/mL | Tapinarof Cream |
|---|---|
| Tapinarof Plasma PK Parameters on Day 1: Cmax | 2440 ± 3900 |
The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.
| hour | Tapinarof Cream |
|---|---|
| Tapinarof Plasma PK Parameters on Day 1: Tmax | 2.37 ± 1.19 |
The Cτ is a pharmacokinetic parameter that is the last quantifiable concentration determined directly from individual concentration-time data
| pg/mL | Tapinarof Cream |
|---|---|
| Tapinarof Plasma Concentration: Cτ | 1330 ± 3780 |
Change in pulse vital signs was assessed for clinical relevance
| Beats/Min | Tapinarof Cream |
|---|---|
| Change From Baseline in Vital Signs (Beats/Min) | 0.9 ± 14.40 |
Change in Blood Pressure vital signs was assessed for clinical relevance
| mmHg | Tapinarof Cream |
|---|---|
| Systolic Blood Pressure (mmHg) | 1.1 ± 8.78 |
| Diastolic Blood Pressure (mmHg) | -0.9 ± 6.63 |
Change in Temperature vital signs was assessed for clinical relevance
| degrees C | Tapinarof Cream |
|---|---|
| Change From Baseline in Vital Signs (C) | -0.08 ± 0.402 |
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| +4 = worsened by 4 | 0 |
| +3 = worsened by 3 | 0 |
| +2 = worsened by 2 | 0 |
| +1 = worsened by 1 | 0 |
| 0 - no change | 8 |
| -1 = improved by 1 | 14 |
| -2 = improved by 2 | 8 |
| -3 = improved by 3 | 2 |
| -4 = improved by 4 | 0 |
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Number of Subjects Who Have a Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Score of Almost Clear (0 or 1) and at Least a 2-grade Reduction From Baseline | 8 |
The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Number of Subjects With ≥50%, Improvement in Eczema Area and Severity Index (EASI) Score | 20 |
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Number of Subjects With ≥75%, Improvement in Eczema Area and Severity Index (EASI) Score | 7 |
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Number of Subjects With ≥90%, Improvement in Eczema Area and Severity Index (EASI) Score | 4 |
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
| scores on a scale | Tapinarof Cream |
|---|---|
| Mean Change in Eczema Area and Severity Index EASI From Baseline to Day 28 | -12.16 ± 9.742 |
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
| % change from baseline | Tapinarof Cream |
|---|---|
| Percent Change in Eczema Area and Severity Index EASI From Baseline to Day 28 | -53.38 ± 38.337 |
The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.
| percentage of BSA | Tapinarof Cream |
|---|---|
| Mean Change in Percent of Total Body Surface Area (%BSA) Affected | -21.06 ± 18.789 |
The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.
| % change from baseline | Tapinarof Cream |
|---|---|
| Percent Change in Percent of Total Body Surface Area (%BSA) Affected | -49.40 ± 41.3000 |
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting (0 indicates no inflammatory signs of atopic dermatitis and 4 indicates disease is widespread). The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. %BSA is a static assessment made without reference to previous scores and will be evaluated 0-100%. The computation is referenced below, and no unit is applicable for this outcome measure. A negative change indicates improvement in disease. \[Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)\]
| unitless | Tapinarof Cream |
|---|---|
| Mean Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values | -85.15 ± 65.848 |
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Score of 0 indicates no inflammatory signs of atopic dermatitis and a 4 indicates disease is widespread in extent. The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores. Computation: Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)
| % change from baseline | Tapinarof Cream |
|---|---|
| Percent Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values | -62.77 ± 35.290 |
The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.
| Units on a scale | Tapinarof Cream |
|---|---|
| Mean Change in Average Weekly Peak Pruritus Numerical Rating Scale (PP-NRS) Score | -4.155 ± 2.4558 |
The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.
| Participants | Tapinarof Cream |
|---|---|
| Achieved ≥ 4-Point Reduction from Baseline in the Average Weekly PP-NRS Score | 14 |
| Failure to Achieve a ≥ 4-point Reduction from Baseline in the Average Weekly PP-NRS Score | 18 |
Collected over Baseline to Day 28 for subjects enrolling in Long-Term Extension (LTE), otherwise to Day 35. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tapinarof Cream | 0/36 (0%) | 0/36 (0%) | 8/36 (22.2%) |
| Event | Tapinarof Cream |
|---|---|
| HeadacheNervous system disorders | 3/36 |
| VomitingGastrointestinal disorders | 2/36 |
| NauseaGastrointestinal disorders | 1/36 |
| FolliculitisInfections and infestations | 1/36 |
| InfluenzaInfections and infestations | 1/36 |
| PustuleInfections and infestations | 1/36 |
| LymphadenopathyBlood and lymphatic system disorders | 1/36 |
| Tranaminases increasedInvestigations | 1/36 |
| ErythemaSkin and subcutaneous tissue disorders | 1/36 |
| Age, Categorical(Participants) | Tapinarof Cream |
|---|---|
| <=18 years | 36 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | Tapinarof Cream |
|---|---|
| Mean | 8.9 ± 4.85 |
| Sex: Female, Male(Participants) | Tapinarof Cream |
|---|---|
| Female | 12 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Tapinarof Cream |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Tapinarof Cream |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 27 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Validated Investigator Global Assessment for Atopic Dermatitis(Participants) | Tapinarof Cream |
|---|---|
| 0 - Clear | 0 |
| 1 - Almost Clear | 0 |
| 2 - Mild | 0 |
| 3 - Moderate | 28 |
| 4 - Severe | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Aug 2022, 9 months.
Results were first posted in Sep 2025, 3 years after primary completion. A results delay was requested in Jan 2023.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tapinarof